SCHEMBL2439155

SCHEMBL2439155

CCOC(=O)COc1ccc(C(C)=O)cc1C

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.57
ESR1 P03372 1/20 0.55
CREBBP Q92793 1/20 0.51
ALDH1A1 P00352 2/20 0.50
KDM4E B2RXH2 1/20 0.50
MEN1 O00255 1/20 0.50
HPGD P15428 1/20 0.50
CASP1 P29466 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
HSD17B10 Q99714 1/20 0.50
MAPT P10636 2/20 0.49
CYP1A2 P05177 1/20 0.48
CYP2C9 P11712 1/20 0.48
HIF1A Q16665 1/20 0.48
TAS1R3 Q7RTX0 1/20 0.48
TAS1R1 Q7RTX1 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3019729 0.90 KMT2A (0.60) KMT2AESR1CREBBPALDH1A1HPGD
SCHEMBL2010422 0.89 KMT2A (0.66) KMT2AESR1CREBBPALDH1A1KDM4E
SCHEMBL3018404 0.88 KMT2A (0.64) KMT2AESR1ALDH1A1KDM4EHPGD
SCHEMBL1245355 0.86 KMT2A (0.55) KMT2ACREBBPALDH1A1KDM4EMEN1
SCHEMBL1642727 0.85 CREBBP (0.68) KMT2ACREBBPALDH1A1MEN1HPGD
SCHEMBL7465120 0.85 KMT2A (0.78) KMT2ACREBBPALDH1A1MEN1MAPT
SCHEMBL5531456 0.85 KMT2A (0.54) KMT2AESR1CREBBPALDH1A1KDM4E
SCHEMBL2007531 0.85 ALDH1A1 (0.54) KMT2ACREBBPALDH1A1KDM4EMEN1
SCHEMBL13847696 0.84 ESR1 (0.52) KMT2AESR1ALDH1A1KDM4EMEN1
SCHEMBL7328604 0.84 ESR1 (0.52) KMT2AESR1ALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2582674-B1 GPR120 RECEPTOR AGONISTS AND USES THEREOF CYMABAY THERAPEUTICS INC (US) 2014-10-01 EP disclosed
US-8822519-B2 Compound with agitation effect on peroxisome proliferator-activated receptor process for its preparation and use thereof ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) 2014-09-02 US disclosed
US-8822519-B2 Compound with agitation effect on peroxisome proliferator-activated receptor process for its preparation and use thereof ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) 2014-09-02 US disclosed
CN-103980235-A GPR120 receptor agonists and uses thereof CYMABAY THERAPEUTICS INC 2014-08-13 CN disclosed
CN-102307860-B GPR120 receptor agonists and uses thereof METABOLEX INC 2014-07-02 CN disclosed
US-20140121246-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2014-05-01 US disclosed
US-8598374-B2 GPR120 receptor agonists and uses thereof METABOLEX, INC. (US) 2013-12-03 US disclosed
US-8476308-B2 GPR120 receptor agonists and uses thereof METABOLEX, INC. (US) 2013-07-02 US disclosed
US-8476308-B2 GPR120 receptor agonists and uses thereof METABOLEX, INC. (US) 2013-07-02 US disclosed
US-8476308-B2 GPR120 receptor agonists and uses thereof METABOLEX, INC. (US) 2013-07-02 US disclosed
US-20070203155-A1 Compounds And Compositions As Ppar Modulators IRM LLC (BM) 2007-08-30 US disclosed
WO-2007056497-A1 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS IRM LLC (BM) 2007-05-18 WO disclosed
WO-2007056366-A2 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS IRM LLC (BM) 2007-05-18 WO disclosed
WO-2007036727-A1 CONDENSED PYRAZOLE DERIVATIVES AS PPAR AGONISTS II INPHARMATICA LIMITED (GB) 2007-04-05 WO disclosed
WO-2007036727-A1 CONDENSED PYRAZOLE DERIVATIVES AS PPAR AGONISTS II INPHARMATICA LIMITED (GB) 2007-04-05 WO disclosed
EP-1749003-A1 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS IRM LLC (BM) 2007-02-07 EP disclosed
EP-1748993-A1 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS IRM LLC (BM) 2007-02-07 EP disclosed
WO-2005116016-A1 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS IRM LLC (BM) 2005-12-08 WO disclosed
WO-2005116000-A1 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS IRM LLC (BM) 2005-12-08 WO disclosed
CN-1507442-A Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors 2004-06-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203155-A1 Compounds And Compositions As Ppar Modulators PPARG, PPARA, PPARD KMT2A 3698/4885ESR1 316/4885CREBBP 48/4885
US-20140121246-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR KMT2A 2862/4885ESR1 831/4885CREBBP 1284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.